Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Common Equity (2022 - 2024)

Adial Pharmaceuticals' Common Equity history spans 3 years, with the latest figure at $5.9 million for Q3 2024.

  • For Q3 2024, Common Equity rose 151.52% year-over-year to $5.9 million; the TTM value through Sep 2024 reached $5.9 million, up 151.52%, while the annual FY2023 figure was $4.1 million, 24.63% up from the prior year.
  • Common Equity for Q3 2024 was $5.9 million at Adial Pharmaceuticals, up from $4.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $10.7 million in Q1 2022 and bottomed at $1.4 million in Q1 2023.
  • The 3-year median for Common Equity is $4.3 million (2024), against an average of $5.0 million.
  • The largest annual shift saw Common Equity plummeted 86.55% in 2023 before it skyrocketed 325.16% in 2024.
  • A 3-year view of Common Equity shows it stood at $3.3 million in 2022, then increased by 24.63% to $4.1 million in 2023, then surged by 44.08% to $5.9 million in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Common Equity are $5.9 million (Q3 2024), $4.3 million (Q2 2024), and $6.1 million (Q1 2024).